Grimes & Company’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-47,863
| Closed | -$95.2K | – | 388 |
|
|
2024
Q3 | $95.2K | Hold |
47,863
| – | – | ﹤0.01% | 356 |
|
|
2024
Q2 | $168K | Buy |
47,863
+893
| +2% | +$3.13K | 0.01% | 335 |
|
|
2024
Q1 | $130K | Sell |
46,970
-893
| -2% | -$2.47K | ﹤0.01% | 331 |
|
|
2023
Q4 | $81.4K | Sell |
47,863
-1,116
| -2% | -$1.9K | ﹤0.01% | 320 |
|
|
2023
Q3 | $50.4K | Buy |
48,979
+1,175
| +2% | +$1.21K | ﹤0.01% | 293 |
|
|
2023
Q2 | $55.5K | Buy |
47,804
+10,106
| +27% | +$11.7K | ﹤0.01% | 300 |
|
|
2023
Q1 | $56.9K | Buy |
37,698
+21,938
| +139% | +$33.1K | ﹤0.01% | 291 |
|
|
2022
Q4 | $39.4K | Hold |
15,760
| – | – | ﹤0.01% | 283 |
|
|
2022
Q3 | $67K | Buy |
15,760
+224
| +1% | +$952 | ﹤0.01% | 266 |
|
|
2022
Q2 | $43K | Buy |
15,536
+448
| +3% | +$1.24K | ﹤0.01% | 269 |
|
|
2022
Q1 | $86K | Buy |
15,088
+3,561
| +31% | +$20.3K | ﹤0.01% | 294 |
|
|
2021
Q4 | $105K | Sell |
11,527
-1,625
| -12% | -$14.8K | ﹤0.01% | 290 |
|
|
2021
Q3 | $141K | Buy |
13,152
+1,262
| +11% | +$13.5K | 0.01% | 292 |
|
|
2021
Q2 | $185K | Buy |
+11,890
| New | +$185K | 0.01% | 289 |
|